呋塞米在腹膜透析患者中的药代动力学与药效学
Pharmacokinetic and Dynamic of Furosemide in Peritoneal Dialysis Patients.
作者信息
Lamarche Caroline, Pichette Maude, Ouimet Denis, Vallée Michel, Bell Robert, Ouellet Georges, Stewart John, Pichette Vincent
机构信息
Department of nephrology, Maisonneuve-Rosemont Hospital, Montreal, Canada.
Sanofi Canada, Laval, Quebec.
出版信息
Perit Dial Int. 2016 Jan-Feb;36(1):107-8. doi: 10.3747/pdi.2014.00328.
The aim of our study was to evaluate the efficacy and bioavailibility of a commonly used oral furosemide dose (500 mg) compared to a 250 mg intravenous (IV) dose in PD patients with significant residual renal function (urine volume > 100 mL). We also evaluated the immediate blood pressure effect in these patients. The data were obtained from a study we performed for the homologation of a 500-mg dose of furosemide by Health Canada.
我们研究的目的是评估常用口服呋塞米剂量（500毫克）与250毫克静脉注射剂量相比，在有显著残余肾功能（尿量>100毫升）的腹膜透析（PD）患者中的疗效和生物利用度。我们还评估了这些患者的即时血压效应。数据来自我们为加拿大卫生部对500毫克剂量呋塞米进行 homologation 而开展的一项研究。
Zotero 插件